27.81
0.00 (0.00%)
0.00 (0.00%)
Upgrade to Real-Time
Afterhours (Closed)
Best deals to access real time data! |
|
Big Cap Pro
Monthly Subscription
for only
|
|
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
|
|
Level 1 Starter
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Revance Therapeutics Inc | RVNC | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Low Price | High Price | Open Price | Close Price | Last Traded  |
|
|---|---|---|---|---|---|---|---|---|
| 0.23 | 0.83% | 27.81 | 27.25 | 27.97 | 27.57 | 27.58 | 00:00:05 |
| Bid Price | Ask Price | Spread | Spread % | News | |
|---|---|---|---|---|---|
| 24.33 | 36.99 | 12.66 | 34.23% | - | - |
| Stock Trades | Traded Volume | VWAP | Dollar Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 11,178 | 1,401,300 | $ 27.68 | $ 38,784,179 | 1,053,599 | 9.88 - 27.97 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 16:59:04 | formt | 7,848 | $ 27.81 | USD |
Revance Therapeutics Financials
| Market Cap | Shares in Issue | Profit/Loss | Earnings Per Share (EPS) | PE Ratio | Float |
|---|---|---|---|---|---|
| $ 1.49B | 53.40M | $ -142.57M | -3.94 | - | 52.56M |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | - | - |
Revance Therapeutics News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical RVNC Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 24.74 | 27.97 | 24.35 | 26.41 | 763,802 | 3.07 | 12.41% |
| 1 Month | 22.40 | 27.97 | 21.13 | 24.47 | 1,002,720 | 5.41 | 24.15% |
| 3 Months | 17.85 | 27.97 | 15.37 | 20.51 | 894,907 | 9.96 | 55.8% |
| 6 Months | 11.25 | 27.97 | 9.88 | 18.35 | 607,429 | 16.56 | 147.2% |
| 1 Year | 18.00 | 27.97 | 9.88 | 16.42 | 502,026 | 9.81 | 54.5% |
| 3 Years | 21.15 | 37.45 | 9.88 | 21.99 | 366,900 | 6.66 | 31.49% |
| 5 Years | 15.71 | 42.45 | 9.88 | 22.58 | 316,274 | 12.10 | 77.02% |
Revance Therapeutics Description
| Revance Therapeutics Inc is a clinical-stage biotechnology company. It is focused on the development, manufacturing, and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic indications. The company's proprietary peptide technology enables delivery of botulinum toxin type A through two investigational drug product candidates, DaxibotulinumtoxinA for Injection (RT002), or RT002 injectable, and DaxibotulinumtoxinA Topical Gel (RT001), or RT001 topical. The company is pursuing clinical development for RT002 injectable in a broad spectrum of aesthetic and therapeutic indications. It holds rights for all indications of RT002 injectable and RT001 topical, and the pharmaceutical uses of its proprietary peptide technology. |
